trending Market Intelligence /marketintelligence/en/news-insights/trending/ve6fvf3qiexgqo5jds3d1w2 content esgSubNav
In This List

CSPC Pharma's cancer medicine granted US orphan drug designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


CSPC Pharma's cancer medicine granted US orphan drug designation

CSPC Pharmaceutical Group Ltd.'s DP303c was granted the U.S. orphan drug designation to treat gastric cancer.

The designation from the U.S. Food and Drug Administration will help expedite development of the antibody-drug conjugate, which targets the human epidermal growth factor receptor 2, or HER2, protein in the body to fight cancer.

Approximately 15% to 20% of gastric cancer patients are HER2 positive.

The Chinese company said this new type of targeted drug can achieve better efficacy for the treatment of gastric cancer with fewer side effects and prolonged survival.